Evidence map›Paper›PMID 35556144›Full record

ArticleStem cells translational medicine2022

Maturation Delay of Human GABAergic Neurogenesis in Fragile X Syndrome Pluripotent Stem Cells.

Ai Zhang, Irina Sokolova, Alain Domissy, Joshua Davis, Lee Rao, Kagistia Hana Utami, Yanling Wang, Randi J Hagerman, Mahmoud A Pouladi, Pietro Sanna and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Ai ZhangDepartment of Molecular Medicine, Scripps Research, La Jolla, CA, USA.
Irina SokolovaDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Alain DomissyCenter for Computational Biology, Scripps Research, La Jolla, CA, USA.
Joshua DavisDepartment of Molecular Medicine, Scripps Research, La Jolla, CA, USA.ORCID 0000-0001-7324-6018
Lee RaoDepartment of Molecular Medicine, Scripps Research, La Jolla, CA, USA.
Kagistia Hana UtamiDepartment of Physiology, National University of Singapore, Singapore.
Yanling WangDepartment of Molecular Medicine, Scripps Research, La Jolla, CA, USA.
Randi J HagermanMIND Institute, University of California Davis, Sacramento, CA, USA.
Mahmoud A PouladiDepartment of Physiology, National University of Singapore, Singapore.
Pietro SannaDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Michael J BolandInstitute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Jeanne F LoringDepartment of Molecular Medicine, Scripps Research, La Jolla, CA, USA.ORCID 0000-0001-6226-9767
Scripps Institution of Oceanography · USAgency for Science, Technology and Research · SGAspenTech (United States) · USColumbia University · USRush University Medical Center · USUniversity of California, Davis · US

Funding

Modeling drugs of abuse-HIV interactions using iPSC-derived human cerebral organoidsR01DA053801 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI REPUNTE-CANONIGO, VEZ, SANNA, PIETRO P · 2021 to 2025
$4.9M
Autism iPSCs for Studying Function and Dysfunction in Human Neural DevelopmentR33MH087925 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI LORING, JEANNE F · 2011 to 2012
$942k
NIDA NIH HHS R01 DA053801NIH HHS R33MH087925NIMH NIH HHS R33 MH087925
6 · The paper itself

Abstract

Fragile X Syndrome (FXS), the leading monogenic cause of intellectual disability and autism spectrum disorder, is caused by expansion of a CGG trinucleotide repeat in the 5'-UTR of the Fragile X Mental Retardation-1 (FMR1) gene. Epigenetic silencing of FMR1 results in loss of the Fragile X Mental Retardation Protein (FMRP). Although most studies to date have focused on excitatory neurons, recent evidence suggests that GABAergic inhibitory networks are also affected. To investigate human GABAergic neurogenesis, we established a method to reproducibly derive inhibitory neurons from multiple FXS and control human pluripotent stem cell (hPSC) lines. Electrophysiological analyses suggested that the developing FXS neurons had a delay in the GABA functional switch, a transition in fetal development that converts the GABAA channel's function from depolarization to hyperpolarization, with profound effects on the developing brain. To investigate the cause of this delay, we analyzed 14 400 single-cell transcriptomes from FXS and control cells at 2 stages of GABAergic neurogenesis. While control and FXS cells were similar at the earlier time point, the later-stage FXS cells retained expression of neuroblast proliferation-associated genes and had lower levels of genes associated with action potential regulation, synapses, and mitochondria compared with controls. Our analysis suggests that loss of FMRP prolongs the proliferative stage of progenitors, which may result in more neurons remaining immature during the later stages of neurogenesis. This could have profound implications for homeostatic excitatory-inhibitory circuit development in FXS, and suggests a novel direction for understanding disease mechanisms that may help to guide therapeutic interventions.

Indexed as

Autism Spectrum DisorderFragile X SyndromePluripotent Stem CellsEpigenesis, GeneticFragile X Messenger Ribonucleoprotein 1HumansNeurogenesisFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1autismfragile X syndromeGABAergic neuronshESCshuman iPSCsneurogenesis

Identifiers

PMID35556144
PMCPMC9216490
OpenAlexW4226317345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.